The purpose of this study was to investigate the cause of polycythemia occurring in hepatocellular carcinoma-bearing control male B6C3F, mice from 2-yr carcinogenicity studies. Erythrocyte counts and plasma levels of erythropoietin in mice with hepatocellular carcinomas were significantly increased compared with the values in non-tumor-bearing mice. Erythropoietin mRNA in 4 of 5 nontumor-bearing mice was detected in the kidney, but no visible signals for hepatic erythropoietin mRNA in 5 of 5 non-tumor-bearing mice were detected by the reverse transcriptase competitive polymerase chain reaction method. Erythropoietin mRNA was expressed in neoplastic hepatocytes from 8 of 9 hepatocellular carcinoma-bearing mice, and this expression was accompanied by decreased expression of erythropoietin mRNA in the kidneys from these mice. The present findings show that polycythemia in hepatocellular carcinoma-bearing mice occurs secondary to excess synthesis of erythropoietin mRNA by neoplastic hepatocytes.
INTRODUCTION
B6C3F1 mice are commonly used in carcinogenicity bioassays of medical drugs and chemical compounds and are known to develop spontaneous hepatocellular carcinomas at a relatively high incidence, especially in aged males (5, 10, 16, 25) . Polycythemia has been reported in B6C3F1 mice with spontaneously occurring hepatocellular carcinomas and is characterized by increases in erythrocyte count, hematocrit, hemoglobin concentration, and absolute reticulocyte count and by decreases in mean corpuscular volume and mean corpuscular hemoglobin. This polycythemia is believed to be a consequence of increased circulating erythropoietin levels derived from neoplastic hepatocytes (12, 13) . Erythropoietin, a glycoprotein hormone that induces erythrocyte differentiation, is primarily formed in peritubular cells in the cortex and outer medulla of the kidney in adults, whereas the liver is the major site of erythropoietin production in the fetus Secondary erythropoiesis associated with excessive erythropoietin synthesis has been reported in humans, and the elevated circulating erythropoietin levels appear to be derived from an ectopic source, such as renal or hepatic tumors (4, 11-13, 15, 17-19, 21) . In addition, (1-3, 7, 14, 20, 26) .
* Address correspondence to: Dr. Akira Horinouchi, Drug Safety Research Laboratories, Pharmaceutical Development Division. Takeda Chemical Industries, Ltd., 2-17-85 Juso Honmachi, Yodogawa-ku, Osaka 532-8686, Japan; e-mail: HorinouchiAkira@takeda.co.jp. erythropoietin production in hepatocellular carcinomas in humans and B6C3F1 mice has been demonstrated using immunohistochemical methods (11, 13, 18, 21) . Increased erythropoietin mRNA has also been reported in human hepatocellular carcinomas (9, 18). Therefore, it was postulated that increased erythropoietin levels in the peripheral blood in B6C3FI mice might be derived from excess production of erythropoietin mRNA by the hepatocellular carcinoma cells rather than being derived from intact kidney, because increases in erythrocytes suppress physiological erythropoietin production in the kidney. Although normal ranges of erythropoietin mRNA are difficult to detect by itz sitir hybridization or northern blotting of kidney and liver (1, 2, 7, 14, 20) , the reverse transcriptase polymerase chain reaction (RT-PCR) has recently been applied for detection of renal and hepatic erythropoietin mRNA in rat and human hepatocellular carcinoma cell lines (8).
There have been no detailed studies regarding erythropoietin mRNA synthesis by neoplastic hepatocytes and kidney in B6C3F1 mice. In the present study, we demonstrate the presence of erythropoietin mRNA in hepatocellular carcinoma cells and kidney of male B6C3F1 mice by RT-PCR and discuss the pathogenesis of polycythemia in these mice bearing spontaneous hepatocellular carcinomas.
MATERIALS AND METHODS Anintals. Male B6C3F1 mice were obtained at 4 wk of age from a commercial breeding colony (CLEA Japan, 682 0192-6233/98$3.00+S0.00 Tokyo) and used as controls for 2-yr carcinogenicity bioassays conducted at the Gotemba Laboratory, Bozo Research Center (Gotemba, Shizuoka, Japan). They were maintained in individual cages in environmentally controlled animal rooms, allowed free access to tap water and a pelleted laboratory animal diet (CRF-1, Oriental Yeast Co., Tokyo), and necropsied at 110 wk of age. Final body weights were 39.8-47.8 g in non-tumor-bearing mice and 30.4-42.9 g in hepatocellular carcinoma-bearing mice. Based upon necropsy findings and histopathology, 5 mice without hepatic nodules or tumors in 'any other organs and tissues (about 40 organs and tissues were examined) and 11 mice with hepatocellular carcinomas and splenomegaly (spleen length >19 mm) were selected for the present study.
Hematology and Plasnia Erythropoietiit Assay. On the day of necropsy, blood samples were collected with a heparinized syringe from the abdominal vena cava of all 16 mice under ether anesthesia and transferred to blood collection tubes (SB-45, Toa Medical Electronics, Kobe) containing an anticoagulant (EDTA-2K). Part of the heparinized blood was used for hematological examination. The values of the following parameters were determined or calculated with an automated hematology analyzer (Coulter Counter T890, Japan Scientific Instruments Co., Tokyo): erythrocyte count, hematocrit, hemoglobin concentration, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), leukocyte count, and platelet count. The remaining blood was centrifuged at 3,000 rpm for 10 min to obtain plasma for the erythropoietin assay. Plasma erythropoietin concentrations were determined by a radioimmunoassay method (12-14). The plasma samples were stored in a freezer at -20°C prior to analysis.
Extraction of Total RNA. The following frozen tissues were used for extraction of total RNA: 9 hepatocellular carcinomas, 5 kidneys from hepatocellular carcinomabearing mice, and normal liver and kidney from nontumor-bearing mice. The organs (-100 mg) were weighed and then immediately homogenized individually in 1 ml TRIZOL reagent (GIBCO BRL, Rockville, MD) containing 50% (w/v) phenol and 47% (w/v) guanidine thiocyanate using a Teflon-glass homogenizer on ice. After incubation for 5 d n at room temperature, 0.2 ml of chloroform was added to each 1.0-ml aliquot of homogenate, and samples were shaken vigorously for 15 sec. After further incubation for 3 min at room temperature, the samples were centrifuged at 12,000 X g for 10 min at 4"C, the aqueous layer was transferred into fresh tubes, and 0.5 ml of isopropanol for each 1.0 ml of TIUZOL reagent used for the initial homogenization was added. After incubation for 3 min at room temperature, the samples were centrifuged at 12,000 X g for 10 min at 4"C, the supernatant was removed, the RNA pellet was washed once with 1 ml of 75% ethanol, and the samples were centrifuged at 7,500 X g for 5 min at 4°C. After centrifugation, the supernatant was removed, and the RNA pellet was air-dried and then dissolved in 100 pl of RNase-free water. The concentration of total RNA was calculated by spectrophotometric measurement at 260 nm. RNA samples were stored at -80°C prior to analysis. Unfortunately, total RNA was not isolated in 6 kidneys and 2 hepatic nodules in hepatocellular carcinoma-bearing mice because the samples were used for preliminary examination.
DNase Treatment for Total RNA. DNase treatment was performed on 1 pg of total RNA in 1 pl of 1OX DNase I reaction buffer (200 mhi,Tris-HCI, pH 8.4, 20 mhi MgClz and 500 mhl KCl), 1 p1 of DNase I (Amplification, 1 U/pl) and RNase-free water in a final volume of 10 p1. After incubation for 15 min at room temperature, 1 p1 of 25 mi EDTA (pH 8) was added to each sample tube, and then the samples were heated for 10 min at 65°C.
Reverse Transcription of RNA into cDNA. Seven microliters of RNA solution treated with DNase I were reverse transcripted into first strand cDNA in 0.5 m f dNTPs, 0.1 pg of random primer (GIBCO BRL), 4 p1 of 5 X first strand buffer (250 mhi Tris-HC1, pH 8.3, 375 mi KCl, 15 mi MgCI2, and 50 mi dithiothreitol), 10 m dithiothreitol, 200 U Moloney murine leukemia virus reverse transcriptase (GIBCO BRL), and RNase-free water in a final volume of 20 p1. The reaction was allowed to proceed for 1 hr at 37°C. The transcription reaction was terminated by heating the samples at 70°C for 10 min.
Competitive PCR. The reaction mixture consisted of 0.2 m~ dNTPs, 0.5 p h i of sense and antisense primers, 5 p1 of 1OX PCR buffer (100 m Tris-HC1, pH 8. 3, 500 mi KCl, and 1% Triton X-loo), 1.5 mM MgCI,, 1.25 U rTaq DNA polymerase (TOYOBO, Osaka, Japan), and RNase-free water. Then 20 pl of cDNA solution and 2 p1 of a dilution series containing known amounts of the competitor were added. The final volume for PCR was 50 p1. The oligonucleotide primers were constructed based on the published sequence of the mouse erythropoietin gene (22) . The sequences of these primers, 5'-GTG GAA GAA CAG GCC ATA GA-3' (sense) and 5'-AG TAC CCG AAG CAG TGA AGT-3' (antisense), are from exon I11 for mouse erythropoietin DNA. PCR was then performed for 40 cycles after an initial denaturation for 2 min at 94°C. The cycle number was chosen to give bands. readily visualized after ethidium bromide staining. The amplification profile of each cycle consisted of denaturation at 94°C for 1 min, primer annealing at 60°C for 1.5 min, and elongation at 72°C for 2 min (GeneAmp PCR System 9700, PE Applied Biosystem). PCR products were electrophoresed using 2% agarose (Agarose X, Wako, Japan) and visualized after staining with 1 pg/d of ethidium bromide. The 200 base pairs of a competitor DNA (MIMIC DNA) were prepared with a special PCR kit ( M I M I P Construction kit, CLONTECH, Palo Alto, CA).
Histopatlzology. Liver and kidney tissues were fixed in neutral 10% neutral phosphate-buffered formalin. Tissues were routinely processed, embedded in paraffin, cut at a thickness of 2-4 pm, stained with hematoxylin and eosin, and examined using a light microscope. Diagnosis of hepatocellular carcinoma was based upon published criteria (16).
Statistics. For statistical analyses of hematology and plasma erythropoietin concentrations, the data were first tested for homogeneity of variance (F-test) between nontumor-bearing and hepatocellular carcinoma-bearing mice (23) . If the variances were homogeneous, Student's t-test was applied, and if the variances were heterogeneous, the Aspin and Welch t-test was performed to compare the mean values of non-tumor-bearing mice with those of hepatocellular carcinoma-bearing mice. All statistical tests were conducted at 5% and 1% 2-tailed probability levels using the SAS function PROBMC (24) . Table I . Significant increases in erythrocyte count, hemoglobin concentration, and hematocrit were noted in hepatocellular carcinoma-bearing mice when compared with those values for non-tumor-bearing mice. Platelet and leukocyte counts, MCH, MCV, and MCHC in the carcinoma-bearing mice were comparable to those in non-tumor-bearing mice. Plasma erythropoietin concentrations are presented in Table 11. Mean plasma erythropoietin levels for the nontumor-bearing group and the carcinoma-bearing group were 20.9 and 49.4 mU/ml, respectively (p = 0.00007).
RESULTS

Hematology data are presented in
Total cellular RNAs were isolated in the intact liver and kidney in non-tumor-bearing or from hepatocellular carcinomas and kidneys from hepatocellular carcinomabearing mice. These total RNAs were reverse transcribed using oligo(dT), and resulting cDNA was amplified using sense and antisense primers of exon I11 for mouse eryth- ropoietin DNA. A product of molecular weight (170 bp) corresponding to that expected for a cDNA fragment produced by the amplification primers was detected in hepatic nodules in the carcinoma-bearing mice and in the kidney in non-tumor-bearing mice (Fig. 1) . A product of molecular weight (200 bp) corresponding to that expected for a MIMIC DNA fragment produced by the amplification primers was also detected in the concentration of 2 and 200 amol (amol = 1 X mol) but was not detected in the concentration of 0.02 amol ( Fig. 1 and Table 111 ).
Renal erythropoietin mRNA in 4 of 5 non-tumor-bearing mice was detected in the lane amplified with 0.02 and 2 amol of MIMIC DNA (lanes 5 and 6). No visible signals for renal erythropoietin mRNA were detected in any non-tumor-bearing mice in the other lane amplified with 200 amol of MIMIC DNA (lane 4). However, no visible signals for hepatic erythropoietin mRNA in all non-tumor-bearing mice were detected in any lane amplified with any concentration of MIMIC DNA (lanes 1-3) .
Erythropoietin mRNA in the hepatic nodules in 8 of 9 hepatocellular carcinoma-bearing mice was detected in the lanes amplified with 2 and 0.02 amol of MIMIC DNA (lanes 8 and 9). Erythropoietin mRNA in the hepatic nodules in 3 of 9 carcinoma-bearing mice were detected in the lane amplified with 200 amol of mimic DNA (lane 7). However, no visible signals for renal erythropoietin mRNA in carcinoma-bearing mice were detected in any lane amplified with any concentration of MIMIC DNA (lanes 10-12).
Histopathological examination revealed hepatocellular carcinoma with or without hepatocellular adenoma in all hepatocellular carcinoma-bearing mice. Necrosis in the : 200 a m o h b e in lanes 1, 4, 7, and 10; 2 amoYtube in lanes 2, 5, 8, and 11;  0.02 amoVtube in lanes 3, 6, 9, and 12 . hepatic nodule were mainly observed in the mice that had no visible signal for erythropoietin mRNA in the gel stained with ethidium bromide. No tumors were observed in the kidney in either the carcinoma-bearing or the nontumor-bearing mice.
DISCUSSION
The liver is the major extrarenal erythropoietin-producing organ in humans, rats, and mice, and it plays a dominant role in fetal erythropoetin production (1-3, 7, 20, 26) . We speculate that hepatocellular carcinomas in B6C3F, mice reexpress the dominant hepatic production of erythropoietin seen in fetal development. In the hepatic nodule(s), erythropoietin mRNA was increased in all hepatocellular carcinoma-bearing mice, except for 1 tumor with extensive necrosis. These results demonstrate that neoplastic hepatocytes are the primary site of excess erythropoietin production. Polycythemia has been reported in humans with hepatocellular carcinomas, and in these cases plasma erythropoietin concentration from hepatic vein blood samples was increased compared with that from hepatic artery, and erythropoietin-positive neoplastic hepatocytes were observed by immunohistochemical staining (11, 18, 21) . These findings strongly suggest the cause of polycythemia is excessive erythropoietin production derived from neoplastic hepatocytes. In hepatocellular carcinoma-bearing mice, erythropoietin-positive neoplastic hepatocytes were observed by immunohistochemistry and increased plasma erythropoietin was also seen in the peripheral blood (17).
Because the kidney is the major erythropoietin-producing organ in humans, rats, and mice (1, 2, 7, 8, 14) , we speculate that renal erythropoietin production in hepatocellular carcinoma-bearing mice was suppressed by increased erythrocytes (hyperoxia). Actually, the renal erythropoietin mRNA levels in these carcinoma-bearing mice were decreased when compared to those in nontumor-bearing mice. The suppressed renal erythropoietin expression in the carcinoma-bearing mice might be a consequence of systemic hyperoxia caused by increased erythrocytes in the peripheral blood and local hyperoxia in the kidney. In hypertransfused mice, the polythythemia induced by the transfused erythrocytes suppressed serum and/or plasma erythropoietin (6). In those mice, the hematocrit was 70% reticulocytes were absent from the peripheral blood, and incorporation of Fes9 into erythrocytes was <0.2%. Suppression of renal erythropoietin mRNA production in hepatocellular carcinoma-bearing mice might be also due to excess circulating erythrocytes.
In summary, semiquantitation of erythropoietin mRNA in the kidney and liver in hepatocellular carcinoma-bearing mice has provided new information that the cause of polycythemia is excess production of erythropoietin mRNA derived from neoplastic hepatocytes but not from the kidney.
